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ABSTRACT
A Grant Proposal to Evaluate the Effect Antibiotic TB Treatment has on the Gut Microbiota and on
Metabolic Functions of Pediatric TB Patients in Dekalb County
By
Oluwatobiloba Akingbade
July 28, 2017
INTRODUCTION: This capstone project is modeled after a National Institutes of Health R21 grant
application to evaluate the relationship between tuberculosis (TB) antibiotic treatment and 1) gut
microbiota and 2) long-term metabolic functions among pediatric patients less than five years old or
greater than five years old, residing in Dekalb county.
AIM: The proposed study specific aims are to 1) determine the relationship between standard drugsensitive antibiotic TB regimens on the gut microbiota (total density and taxa) at the time of TB
treatment completion and one-year after treatment completion; 2) determine the relationship between
standard drug-sensitive antibiotic TB regimens and metabolic biomarkers (Short Chain Fatty Acids
(SCFAs), amino acids (Branched Chain and Aromatic), cholesterol, and glucose) at the time of
treatment and one-year follow-up.
SIGNIFICANCE: In the last ten years, antibiotic use has increased substantially, correlating with the
increase incidence of childhood obesity and diabetes. This trend may partially be explained by an
association between broad-spectrum antibiotic usage during childhood and the dysbiosis of the gut
microbiome. The disruption of the gut microbiota induces the dysregulation of metabolic pathways,
which may lead to the increased risk of developing obesity and diabetes. In 2015, TB accounted for 1
million incident cases in children. Given antibiotic treatment for TB requires exposure to multiple
antibiotics for more than 6 consecutive months, this proposal intends to understand the extent to
which exposure to TB treatment may impact the gut microbiome and whether antibiotic induced
dysbiosis in the gut microbiome has long-term impact on pediatric metabolic function.
APPROACH: Eligibility criteria includes all TB pediatric patients (< 15 years of age) residing in
DeKalb county, receiving care for drug-susceptible pulmonary TB by the DeKalb Refugee Clinic
within the Dekalb County Board of Health. Patients with previous history of diabetes, obesity, or HIV
will be excluded.
STUDY DESIGN: We will perform a prospective cohort study of N=50 pulmonary drug-susceptible
pediatric TB patients from 2018-2020. At the time of baseline, TB treatment completion, and one-year
follow-up the primary measures collected will be total density and taxa distribution of the gut
microbiome. We will also collect SCFA, branched chain and aromatic amino acids, fasting glucose,
A1c, and fasting cholesterol. Baseline measures will act as an internal comparison group for each
patient.
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SPECIFIC AIMS
In 2015, tuberculosis (TB) in children accounted for 1 million incident cases with 210,000 deaths worldwide1.
With the recently improved recommendations for antibiotic TB drug dosages for children2 and the creation of
solid fixed dose combination (FDC) child-friendly formulated TB drugs1, adherence and completion of antibiotic
TB treatment will increase. Subsequently, since treatment can take anywhere from 6 months to 24 months3,
active pediatric TB patients are exposed to prolonged antibiotic TB treatment during crucial developmental
stages. This research will determine the extent to which antibiotic TB treatment affects the gut microbiome.
Currently, little is known about the impact antibiotic TB treatment has on the gut microbiome of pediatric TB
patients. Studies on mice have found that broad-spectrum antibiotic use disrupts the development of early life
gut microbiota causing biodiversity loss (i.e. loss of bacteria strains and a decrease of overall bacteria
abundance)4, 5. Biodiversity loss impacts the metabolic functions of the gut which in turn increases adipose
tissue and the risk of obesity6, 7. This proposal will focus on understanding the relationship between antibiotic
TB treatment and four metabolic biomarkers: Short Chain Fatty Acids (SCFA’s), Amino Acids (Branched Chain
and Aromatic), cholesterol, and glucose. The overarching goal of this study is to understand the impact
antibiotic TB treatment has on the gut microbiome and on metabolic functions.
Human studies reveal that infants who received antibiotics had a reduced frequency of phylum Firmicutes and
a higher frequency of phylum Proteobacteria, two of the eight bacterial divisions in the gut, than infants who did
not receive any antibiotics8. SCFAs are bacterial waste products produced from two phyla’s, Bacteroides and
Firmicutes. Since the gut dysbiosis, induced by antibiotics, decreases the occurrence of Firmicutes, a
production of SCFAs will also decrease9. This leads to a decline in overall health since SCFAs regulate the
homeostasis of various metabolic pathways, such as cholesterol and glucose, which are associated with the
protection and improvement of type 2 diabetes10, 11. Subsequently, phyla Proteobacteria and Firmicutes are gut
bacteria that produce the most abundant amount of amino acids12. The gut microbiota as a whole, through
fermentation of complex carbohydrates, increases the specific production of circulating Branch Chain Amino
Acids (BCAA) and Aromatic Amino Acids (AAA)13. Currently, it is known that BCAA and AAA play a role in
glucose homeostasis and have been identified as predictors for developing diabetes14.
This study hypothesizes that culture confirmed pediatric patients (<5 years old), compared to pediatric
patients (>5 years to 15 years old), who undergo 6 months of antibiotic TB treatment will see a decline
in gut biodiversity (total density, and taxa distribution) and irregular levels of SCFA, amino acids,
cholesterol, and glucose one year after antibiotic TB completion. In 2015, DeKalb’s Health District had the
highest TB case rates (7.9 per 100,000) in Georgia15, making it a suitable setting to evaluate the proposed
hypothesis. The study will be conducted in one of Georgia’s well-established TB clinic, the DeKalb Refugee
Health Clinic in Decatur, Georgia. We will enroll cultured confirmed newly diagnosed TB (n=50) pediatric
patients (who are <5 [n=25] or >5 years [n=25]) and collect measures of biodiversity (total density and taxa
distribution) of the gut microbiota, levels of SCFA’s, amino acids, cholesterol, and glucose before, at TB
treatment completion, and at one-year follow-up.
Aim 1: Determine the relationship and impact of antibiotic TB treatment on the gut microbiota (total density and
taxa distribution) in pediatric patients (<5 and >5 years) at the time of TB treatment completion, and at oneyear follow-up.
Hypothesis 1: Pediatric patients <5 years old, compared to patients >5 to 15 years old, will 1a) have reduced
gut biodiversity (total density and taxa distribution) at the time of TB treatment completion and 1b) persistent
gut dysbiosis one year after TB treatment completion.
Aim 2: Determine the relationship between antibiotic TB treatment and metabolic biomarkers (SCFA’s, amino
acids, cholesterol, and glucose) at the time of treatment and one-year follow-up.
Hypothesis 2: Pediatric patients <5 years old, compared to patients >5 to 15 years old, will 2a) have irregular
levels of SCFA’s, amino acids, cholesterol, and glucose at the time of TB treatment completion and 2b) one
year after TB treatment completion.

8

A. SIGNIFICANCE
The global burden of infectious diseases, such as tuberculosis, has driven an unanticipated rise in
irrational antibiotic use 16, 17. With the global rise in non-communicable diseases, such as obesity and
diabetes18, this intersection may be explained by the dysbiosis of the gut microbiota. The global
estimated incidence of childhood TB has increased from 663,990 in 1990 to 1 million in 201419. Due to the
financial increase of developing countries and the unregulated over the counter trade of antibiotics, individuals
have improved access to antibiotics without any medical consultation or written prescription16, 20, 21. Between
2000 and 2010, antibiotic use increased 35% worldwide22, and within pediatric patients pre-school aged
children had a 72% higher prevalence of antibiotic use than school age children and adolescents23.
Subsequently, during the same time, the global prevalence of childhood obesity increased from 4.2% in 1990
to 6.7% in 2010 with about 81% of these individuals residing in developing countries24, 25. Although, for over a
century epidemiological studies have focused on the effect diabetes mellitus (DM) has on TB susceptibility and
have concluded that DM increases the risk and severity of TB26, there is an alternative hypothesis that could
better explain these trends. Numerous studies have shown an association between antibiotic use and the
alteration in the gut microbiota4, 6 which influences the development of type 2 diabetes27. This proposal intends
to explore whether antibiotic TB treatment alters the gut microbiome, which may consequently increase the risk
of non-communicable diseases such as obesity and diabetes in children.
The duration and the amount of dosages taken during antibiotic TB treatment in pediatric patients is a
cause for concern on its effects on the gut microbiota and on what that implies for the future of
pediatric TB treatment. Antibiotic TB treatment is divided into two phases. The first phase, called the
intensive phase, lasts about two months and the second phase, called the continuous phase, lasts either four
to seven months28-30. The purpose of the intensive phase is to kill off most of the TB bacteria as quickly as
possible, which is why more antibiotic drug combinations are utilized in this phase than the continuous phase29,
30. The continuous phase then intends to eliminate any dormant TB bacteria29, 30. The recommended regimen
for pediatric patients newly diagnosed with pulmonary drug-susceptible TB is a combination of 50 mg of
isoniazid (INH), 75 mg of rifampin (RIF), and 150 mg of pyrazinamide (PZA) for seven or five days a week
during the intensive phase29. During the continuous phase, a combination of 50 mg of INH and 75 mg of RIF is
taken29. This regimen is about 182 to 130 dosages for the duration of the TB treatment and is only utilized for
drug susceptible TB28. Other forms of TB, like TB meningitis, add more antibiotics to the regimen28-30.
Currently, little is known about the effects of consuming this amount of antibiotic dosages for TB has on the gut
microbiota. If TB treatment does significantly cause the dysbiosis of the gut microbiota science may need to 1)
create treatments, like probiotics, that are implemented after treatment to bring the gut microbiota to its proper
equilibrium and/or 2) the transplantation of the gut microbiota from one healthy individual to an individual who
endured TB treatment. As for now, by deducing from studies on broad spectrum antibiotic use, this proposal
intends to conceive how antibiotic TB treatment causes dysbiosis in the gut microbiota.
The colonization and configuration of an infant’s gut microbiota are important for its overall health.
The introduction of antibiotic treatment, even fleeting, can cause metabolic perturbations leading to
increased adipose tissue4, and early childhood obesity31. Upon delivery, most neonates are colonized by
maternal bacteria through the skin, vaginal tract, and feces32. This colonization molds the compositions of the
infants gut microbiota33 which increases in richness and diversity to adult-associated configuration by the age
of 3 years34. The adult composition of the gut microbiota consists of the highest bacteria cell density of any
ecosystem recorded but the lowest diversity of 8 bacterial divisions, with the dominant phyla Firmicutes,
Bacteroides, Actinobacteria, and Verrucomicrobia35, 36. The gut microbiota is critical in regulating the
permeability of the gastro-intestinal mucosa lining, which is important in preventing the colonization of
pathogens. It is also important in the synthesis of amino acids, production of vitamins, and the fermentation
and absorption of dietary polysaccharides37. Since infants are still developing their gut microbiota, their
ecosystem is dependent on their diet and environment,38 which is why any form of antibiotic use, especially for
the duration in which antibiotic TB treatments are applied, can cause damage to the equilibrium of the gut
microbiota and lead to the health decline of the host. Various human studies have shown that infants who were
given broad spectrum antibiotics had a reduction of phyla Actinobacteria and Firmicutes, and were dominated
by phylum Proteobacteria even eight weeks after antibiotic treatment39, 40. Studies agree that the gut microbiota
1) promotes the fermentation of indigestible polysaccharides into SCFA 35, 41 and 2) at persistent dysbiosis
increases levels of amino acids42, consequently leading to the production of body fat and insulin resistance41.
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Scientific Premise: The bacterial waste products produced during colonic fermentation43, SCFA, can
potentially protect against diet induced obesity11 and diabetes44. SCFA consist of acetate, propionate, and
butyrate, and are produced by Bacteroides (acetate and propionate producing organism) and Firmicutes
(butyrate producing organisms)43, 45. Their main role is to be a source of energy for colonic epithelial cells,
which receive 60-70% of their energy from mostly Butyrate46. SCFAs, acetate, and butyrate46, regulate the
metabolism of fatty acids by activating fatty acid oxidation and inhibiting lipolysis. This consequently leads to
the reduction of free fatty acids and the body weight of an individual47. SCFAs also regulate the metabolism of
glucose and lowers the production of plasma glucose levels in the blood. Propionate and acetate regulate
cholesterol metabolism and lower cholesterol plasma and serum concentrations respectively47. In a human
study by Yamashiro et al. reduced levels of the phylum Firmicutes, acetate, and propionate was associated
with higher levels of HbA1c and LDL cholesterol48. These findings implicate that the decrease production of
SCFA could potentially lead to hyperglycemia and hyperlipidemia, which could predispose individuals to Type
2 diabetes46.
The gut microbiota also produces amino acids from energy created by the fermentation of dietary
carbohydrates13 particularly those of Branch-chain (BCAA) (isoleucine, leucine, and valine) and
aromatic amino acids (AAA) (tyrosine, and phenylalanine) which have been shown to be predictive of
obesity and diabetes12, 49. Antibiotic induced dysbiosis of the gut microbiota have shown to increase phylum
proteobacteria39 and phylum proteobacteria is one of two phyla’s that produce the most abundant amount of
amino acids12, consequently increasing circulating amino acids. Amino acids aid with glucose homeostasis by
controlling insulin and glucose secretion14. A study conducted by Wang et al. followed non-diabetic individuals
for a 12-year period and discovered that all cases who had high concentrations of either isoleucine, leucine,
valine, tyrosine, and phenylalanine, developed diabetes. Likewise, individuals who had a combined increased
circulating concentration of Isoleucine, tyrosine, and phenylalanine had a 5- to 7-fold higher risk of developing
diabetes49. A proposed mechanism by Krebs et al. found that increased concentration of amino acids induces
insulin resistance by impairing glucose transport and/or phosphorylation activity50. The defect in glucose
transport and/or phosphorylation activity would then impair glycogen synthesis and lead to obesity51 and type 2
diabetes52. Another possible mechanism by which increased concentrations of amino acids promote obesity
and type 2 diabetes is through insulin secretion49. Studies infusing BCAA into healthy human subjects
decreases insulin sensitivity and studies depriving BCAA in animal models improved insulin sensitivity14.
Through the chronic elevation of amino acids, individuals could develop hyperinsulinism causing pancreatic
beta-cell failure49, 53.
B. Innovation
1). Clinical trials focusing on tuberculosis treatment and its effects on the gut microbiota have not
been previously conducted. Our proposal is unique because we aim to gain a better understanding of the
long-term health implications of TB treatment. Currently, there has only been one study that examines the
relationship between TB and gut microbiota. It focuses on how the alteration of the gut microbiota can cause
TB54. Our study will bring insight into the composition of gut microbiota in TB burdened individuals, negative
consequences of TB treatment on bacterial phyla’s, and the long-term effects of TB treatment on gut
microbiota.
2). Currently, epidemiological and clinical studies are focused on TB susceptibility of Diabetes Mellitus
(DM) patients26. Our studies hypothesis chooses to break from current consensus of thinking and
prospectively follow individuals through a cohort study to observe if and/or how TB treatment leads to the
increased risk of diabetes. This approach will give our study a unique understanding of the time frame in which
individuals would need medical intervention to rectify the effects of TB treatment on their risk of diabetes. This
approach will be executed by detecting metabolic biomarkers that are indicative of obesity.
C. APPROACH
C1. Overall goal: The primary motivation for this R21 proposal is to evaluate the hypothesis that antibiotic TB
treatment in pediatric patients (children <5 years) causes the dysbiosis of gut microbiota by disrupting total
density, and taxa distribution. We will also evaluate the hypothesis that the dysbiosis of gut microbiota leads to
a disruption of metabolic functions which could be indicative of increased risk of obesity and diabetes in the
future.
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C2. Study Design Overview: We will conduct a prospective cohort study at the Dekalb County Board of
Health consisting of two groups: 1) pediatric patients less than five years old successfully completing drug
susceptible TB treatment, and 2) pediatric patients greater than five to fifteen years old successfully completing
drug susceptible TB treatment. SCFA, fasting BCAA and AAA, fasting glucose levels, A1c, and fasting total
cholesterol levels will be measured at the time of enrollment, at the time of TB treatment completion (6
months), and one year after TB treatment completion (18 months) (Figure 1).
Figure 1: Study Overview Timeline
One year after TB treatment
completion (18 months)

Enrollement (0 months)
TB Infection

TB Treatment

Post- Treatment

Post- Treatment

TB Treatment completion (6
months)

C3. Study Team: We have gathered a strong team of clinicians with a notable background in epidemiologic
research addressing TB and/or the intersection between TB and non-communicable disease. Dr. Matthew
Magee (PI) is an Assistant Professor of Epidemiology and Biostatistics at Georgia State University and has
countless work with the Dekalb Board of Health. Dr. Alawode Oladele (Co-PI) is the medical director of countywide services for Dekalb County Board of Health. A clinical physician practicing family medicine in Decatur,
Georgia, who works closely with the Dekalb Refugee Clinic.
C.4 Participant Eligibility: All study participants will be pediatric patients (<15). Patients will be grouped by
age brackets (<5 years or >5 to 15 years), reside in Dekalb county in Georgia with no history of HIV and
diabetes. Eligibility criteria will be the same for the two study groups. All participants must have drug
susceptible TB: culture confirmed pediatric TB patients who are susceptible to isoniazid or rifampin antibiotics
at the time of TB diagnosis would be eligible for enrollment (see section C6 for enrollment details).
C5. Feasibility: This study will work closely in collaboration with the Dekalb refugee Health Clinic which
evaluates ten new families (2500 adults and children) every week with about 40% of these individual’s younger
than the age of 18. The refugee health clinic provides health and mental screenings, immunizations, and
follow-up and management services for tuberculosis. Dekalb County Board of Health supports a pediatric clinic
as an extension of the Refugee Health Program which provides refugee children medical treatments referrals.
Since most pediatric patients who are suffering from TB are just resettling from a different country, the Dekalb
County Board of Health obtains medical information and assessments. Blood, urine, and stool samples are
collected to screen for metabolic diseases, nutritional status, and infectious diseases.
C6. Participant enrollment: All drug-susceptible pediatric TB patients (<15 years old) who are enrolled in the
TB clinic within the Dekalb Board of Health will have any clinical, laboratory, and hospital records reviewed for
history of HIV, TB, and diabetes. Eligible participants will then be approached to enroll before the start of
antibiotic TB treatment.
C7. Primary study measures: All primary study measures will be evaluated before, at time of TB treatment
completion, and one year after TB treatment with added information from clinical evaluations and
questionnaires. Drug Susceptible TB: Pediatric patients whose TB disease is easily treatable by isoniazid or
rifampin antibiotics at the time of diagnosis. Patients will either be culture confirmed using BACTEC-MGIT or
genetically confirmed using GeneXpert assay to measure drug susceptibility. During the initial time of
enrollment, families will be approached for consent by study team members. Instructions for stool sample
collection and supplies will be explained and delivered to parents at this time. Subsequent stool samples will
be collected during clinic follow-up appointments. After stool samples are collected, they will be sent to the
Institute of Biomedical Sciences at Georgia State University. Samples will be transported in plastic bags
containing a disposable oxygen-absorbing and carbon dioxide-generating agent inside a container kept at 4oC.
This will allow anaerobes sensitive to oxygen a chance to survive the trip to the laboratory55. The gut
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microbiota: Once stool samples are transported to a laboratory they will be divided in two. One-half of the
sample will undergo nucleic acid extraction, using AllPrep PowerFecal DNA/RNA extraction kits (Qiagen) for
16S rRNA sequencing (microbiome assay to characterize the composition of the gut microbiota)56. 16S rRNA
will be generated and sequenced by the Georgia Genomics Facility at University of Georgia. 16s libraries will
be generated by using V3 – V5 primer regions. For data analysis purposes, the Shannon-Wiener diversity
index and the amount of 16s rRNA genes belonging to phyla’s Proteobacteria, Actinobacteria and Firmicutes
will be enumerated. SCFA, BCAA, and AAA: The second half of the stool sample will be used to derivatize
metabolites with 100ul of propyl chloroformate in a reaction system of water/propanol/pyridine at pH 8.0 before
a two-step extraction with hexane. Analysis of derivative samples will then be performed using an Agilent
7890A gas chromatography system coupled to an Agilent 5975C inert XL EI/CI mass spectrometric detector
(GC-MS)(MSD, Agilent Technologies, Santa Clara, CA)42. Any remaining stool sample material and/or nucleic
acid extracts will be frozen at 80oC and stored in the laboratory for future ongoing studies. Fasting glucose,
fasting total cholesterol, and A1C: At the time of enrollment and during clinic follow-up appointments, blood
samples will be collected from each individual. A point of care diagnostic device, Alere Cholestech LDX®
Analyzer (Waltham, USA), will be used to obtain fasting glucose and fasting total cholesterol levels. DCA
Vantage® Analyzer (Siemens, USA) will be used to obtain A1c levels. According to the American Diabetes
Association, guidelines for: 1) Fasting glucose are <100mg/dl normal, 100 -120 mg/dl prediabetes, and ≥126
mg/dl diabetes and 2) A1c are <5.7% is normal, 5.7% - 6.4% is prediabetes, and ≥6.5% is diabetes57.
Individuals who have fasting glucose levels ≥100mg/dl or A1c levels ≥5.7% will be categorized as
hyperglycemic. According to the National Cholesterol Education Program, guidelines for total cholesterol are:
<200 mg/dl is desirable, 200 -239 mg/dl is borderline high, and ≥240 mg/dl is high58. Individuals who either
have borderline high or high will be categorized as hyperlipidemic.
C8. Key covariates: Study team members will conduct questionnaires and extract information from medical
records. Enrolled patients will be able to divulge information on previous demographic characteristics, diet, and
cigarette exposure. Key covariates, shown in Table 1, will be collected at the time of enrollment, at the time of
TB treatment completion, and one year after TB treatment completion (Table 1).
Table 1. Key study measures, measurement methods and timeline
Measure
Method
Study Month†
Gut biodiversity (total density and taxa
GC-MS)(Agilent)
0,6,18
distribution)
SCFA (acetate, propionate, and butyrate)
GC-MS (Agilent)
0, 6, 18
(BCAA) (isoleucine, leucine, and valine)
GC-MS (Agilent)
0, 6, 18
(AAA) (tyrosine, and phenylalanine)
GC-MS (Agilent)
0, 6, 18
Fasting Glucose
FPG (Cholestech)
0, 6, 18
A1c
HbA1c (Vantage)
0, 6, 18
Fasting Cholesterol
Total Cholesterol (Cholestech)
0, 6, 18
Smoking Exposure
Self-report
0,18
Country of Origin
Self-report
0
Age at entrance into U.S.
Self-report
0
Age at enrollment
Self-report
0
Gender
Self-report
0
TBF
Height/ Weight measurment
0, 6, 18
Previous Antibiotic use
Self-report & Medical Chart Abstraction Pre Study*
HIV status
Self-report & Medical Chart Abstraction Pre Study*
Previous Diabetes
Self-report & Medical Chart Abstraction Pre Study*
History of TB
Self-report & Medical Chart Abstraction Pre Study*
† 0 indicates time of study enrollment which is time of TB diagnosis.
Abbreviations: SCFA – short chain fatty acid, BCAA – branch chain amino acids, AAA – aromatic amino
acids, TBF – Total Body Fat. *Pre-study means that measurements will be collected from medical records
before TB treatment.
C9. Data analysis: Aim 1 To determine the association between TB treatment (categorized as 2-level
categorical variables, pediatric patients <5 years old and >5 to 15 years old) and median levels of gut
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biodiversity (total density and taxa distribution) at time of 1a) TB treatment completion (6 months), and 1b) one
year after TB treatment completion. Two linear regression models will be used to measure the association
between the two comparison groups (age of pediatric patients) on median levels of gut biodiversity (on total
density and on taxa distribution) at the time of TB treatment completion and one-year after TB treatment
completion. The F-test and R-squared will be reported to asses if age predicts dysbiosis and how much
variance in dysbiosis can be accounted by age. A t-test will be conducted to determine the significance of age.
A beta coefficient will be used to determine magnitude and direction of the relationship between age and gut
dysbiosis. We will also exam the relationship between the two comparison groups, on total density and taxa
distribution, controlling for three covariates (smoking exposure, country of origin, and age at entrance) by using
two multiple linear regression models. We will test total body fat (TBF) as an interaction variable due to the
possibility that higher TBF induces undiagnosed prediabetes, which may contribute to an increased chance of
developing diabetes after TB treatment (Figure 2). We will also control for confounding variables, previous
history of antibiotic use and sex. Individuals history of previous broad-spectrum antibiotic usage may induce
gut dysbiosis before study enrollment and males tend to have a higher prevalence of metabolic and intestinal
inflammatory diseases compared to women59. Aim 2 To determine the association between TB treatment
(categorized as 2-level categorical variable, pediatric patients <5 years old and >5 to 15 years old) and
metabolic biomarkers SCFAs, BCAA, AAA, cholesterol, and glucose 2a) at the time of TB treatment completion
and 2) one-year after TB treatment completion. We will evaluate acetate, butyrate, propionate, isoleucine,
leucine, valine, tyrosine, and phenylalanine by using 9 linear regression models to evaluate the association
between the comparison groups and all the continuous metabolic biomarkers at TB treatment completion and
one-year after TB treatment completion. The same multiple linear regression model, interaction variable, and
control of confounding variables will be used to evaluated the relationship between age and SCFA, BCAA, and
AAA. To evaluate the categorical dependent variables, cholesterol and glucose, two logistic regression models
will be utilized. The chi-squared, R-squared, and beta coefficient will be assessed.
Odds ratios and 95% confidence intervals will be ascertained from each of these regression models. Known
confounders (HIV, history of TB, and previous diabetes) have been controlled for by screening individuals with
this variable out of the study. Additional covariates that are identified to be confounders will be adjusted for in
the regression models.
Figure 2: Directed Acyclic Graph (DAG) of Central Hypothesis
Gender

Pediatric TB
Patients <5

TB Infection

TB
Treatment
(Exposure)

Dysbiosis Of
Gut
Microbiota

TBF
Irregular
Metabolic
Biomarkers
(Outcome)

Diabetes

Previous
Antibiotic
Use
C10. Sample size: The enrollment goal will be to collect three specimens at each of the time points from 50
pediatric patients. There will be a total of 150 stool specimens collected over the 24-month study period. With
the same logic, we will also be collecting 150 blood samples. We will collect specimens at baseline, six
months, and eighteen months.
C11. Limitations: Due to the small sample size, this proposed study will not be generalizable to all
populations. Since pediatric patients will be enrolled from a refugee clinic, the enrollment population is
representative of foreign countries. Also, the lack of controls makes it difficult to differentiate if the dysbiosis of
the gut microbiota is due to TB treatment or TB disease. Another limitation of this study is the difficulty in
13

controlling the diet of each individual, which can impact the gut microbiota significantly. This proposal did not
account for gender and other factors such as medications that individuals may take during the study period.
C12. Future directions: Results of this prospective cohort R21 proposal will provide novel information for
future studies on the relationship between TB treatment and the dysbiosis of the gut microbiota as well as
metabolic functions. At the time of enrollment, parents of patients, will be asked if they will consent to being
contacted in the future, with the aim to reach the same patients for further studies. Future studies will collect
medical record information and questionnaires to ascertain whom within the groups developed or has an
increased risk of obesity and diabetes. We believe that pediatric patients younger than five years old with
persistent gut dysbiosis at one year after TB treatment will develop an increased risk of a non-communicable
disease (obesity and/or diabetes).
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